TITLE

New drugs and dosage forms

PUB. DATE
April 2014
SOURCE
American Journal of Health-System Pharmacy;4/1/2014, Vol. 71 Issue 7, p520
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on several drugs release in the U.S. in 2014 and their dosage forms including Elosulfase alfa injection from BioMarin Pharmaceutical, Indomethacin capsules from Iroko Pharmaceuticals and Metreleptin for injection from Bristol-Myers Squibb.
ACCESSION #
95053709

 

Related Articles

  • PHASE 3 TRIAL/STUDY OF ALDURAZYME FOR MPS I PROMISING.  // Worldwide Biotech;Aug2002, Vol. 14 Issue 8, p8 

    Reports on the results of the clinical trial of Aldurazyme, an investigational enzyme replacement therapy for patients with mucopolysaccharidosis I.

  • Hemicrania continua: clinical and nosographic update. Rapoport, A.M.; Bigal, M.E. // Neurological Sciences;May2003 Supplement 2, Vol. 24, ps118 

    Hemicrania continua (HC) is an uncommon primary headache syndrome. The main features of HC are: (i) strict unilaterality of the pain (moderate, fluctuating, relatively long-lasting); and (ii) absolute response to indomethacin. These two features may reflect the most reliable characteristics of...

  • Endothelin-1-dependent up-regulation of leptin production in gastric mucosal injury by indomethacin. Slomiany, Bronislaw L.; Slomiany, Amalia // Inflammopharmacology;2005, Vol. 13 Issue 5/6, p455 

    Leptin, a multifunctional hormone that regulates food intake and metabolic and endocrine responses, has emerged recently as an important modulatory factor in gastric mucosal resistance to injury. In this study, we applied the animal model of gastric mucosal injury caused by indomethacin to...

  • Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.  // Orphanet Journal of Rare Diseases;2011, Vol. 6 Issue 1, p55 

    The article presents a European consensus procedure which showed the use of enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) in the treatment of patient having mucopolysaccharidosis type I (MPS I). In this procedure a panel of specialists developed...

  • Therapeutic effect of rebamipide in a modified acetic acid-induced buccal mucosal ulcer model. Ishiyama, Hironobu; Kawai, Kazuyoshi; Azuma, Atsushi; Nagano, Chifumi // Inflammopharmacology;2002, Vol. 10 Issue 4-6, p391 

    Previous studies have suggested that rebamipide, a gastroprotective drug, might be effective for the treatment of aphthous oral ulcers in Behçet's disease patients. The aim of this study was to confirm the effect of rebamipide on experimentally induced stomatitis in a rat acetic acidinduced...

  • Attenuated mucopolysaccharidosis: are you missing this debilitating condition? Lampe, Christina // Rheumatology;Mar2012, Vol. 51 Issue 3, p401 

    The author offers clinical information on mucopolysaccharidosis (MPS), a rare condition often misdiagnosed because of the perception that this condition is a childhood disease. He explains that patients with attenuated or slow-progressing MPS will often fail to initially receive a correct...

  • OSTEOARTHROPATHY IN MUCOPOLYSACCHARIDOSIS TYPE II. NASCU, IOANA; GRIGORESCU-SIDO, PAULA; AL-KHZOUZ, CAMELIA; BUCERZAN, SIMONA; DENES, CARMENCITA; LAZEA, CECILIA // Clujul Medical;2013, Vol. 86 Issue 3, p270 

    Introduction. Mucopolysaccharidosis type II (MPS type II, Hunter syndrome) is a rare (~ 1/1500.000), X-linked inherited disorder (affects boys) due to deficiency of the lysosomal enzyme iduronate sulfatase (Xq.28). The complex clinical picture includes osteoarthropathy with a tendency to flexion...

  • Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. McCarty, Douglas M.; DiRosario, Julianne; Gulaid, Kadra; Killedar, Smruti; Oosterhof, Arie; Van Kuppevelt, Toin H.; Martin, Paul T.; Haiyan Fu // Metabolic Brain Disease;Mar2011, Vol. 26 Issue 1, p9 

    The primary pathology in mucopolysaccharidosis (MPS) IIIB is lysosomal storage of heparan sulfate (HS) glycosaminoglycans, leading to complex neuropathology and dysfunction, for which the detailed mechanisms remain unclear. Using antibodies that recognize specific HS glycoforms, we demonstrate...

  • Structural study on mutant α- l-iduronidases: insight into mucopolysaccharidosis type I. Sugawara, Kanako; Saito, Seiji; Ohno, Kazuki; Okuyama, Torayuki; Sakuraba, Hitoshi // Journal of Human Genetics;May2008, Vol. 53 Issue 5, p467 

    To elucidate the basis of mucopolysaccharidosis type I (MPS I), we constructed structural models of mutant α- l-iduronidases (IDUAs) resulting from 33 amino acid substitutions that lead to MPS I (17 severe, eight intermediate, and eight attenuated). Then, we examined the structural changes in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics